Orrock Janet E, Ilowite Norman T
a Division of Pediatric Rheumatology , The Children's Hospital at Montefiore , Bronx , NY , USA.
Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
Canakinumab, a fully human monoclonal antibody against interleukin-1β, is a relatively new medication approved for treatment of systemic juvenile idiopathic arthritis (SJIA). Here, we review data supporting use of canakinumab for patients with active SJIA, as compared to other available biologic medications.
This article provides an overview of chemistry of canakinumab as well as the phase II and phase III trials that led to approval for treatment of active SJIA. To undertake this review, the authors performed literature search using Pubmed, with keywords 'canakinumab,' 'biologic,' 'anti-IL-1B,' and 'systemic juvenile idiopathic arthritis,' focusing on publications within the last 5 years. Expert commentary: Canakinumab has shown efficacy in treatment of SJIA with active systemic features including fever. There is no evidence to suggest increased risk of macrophage activation syndrome. Its use in the treatment of chronic arthritis without active systemic features has not been approved and warrants further study.
卡那单抗是一种完全人源化的抗白细胞介素-1β单克隆抗体，是一种相对较新的被批准用于治疗全身型幼年特发性关节炎（SJIA）的药物。在此，我们回顾与其他可用生物药物相比，支持卡那单抗用于活动性SJIA患者的数据。
本文概述了卡那单抗的化学性质以及导致其被批准用于治疗活动性SJIA的II期和III期试验。为进行本综述，作者使用PubMed进行文献检索，关键词为“卡那单抗”“生物制剂”“抗IL-1B”和“全身型幼年特发性关节炎”，重点关注过去5年内的出版物。专家评论：卡那单抗已显示出对具有包括发热在内的活动性全身特征的SJIA有效。没有证据表明巨噬细胞活化综合征风险增加。其在无活动性全身特征的慢性关节炎治疗中的应用尚未获得批准，值得进一步研究。
